Jeremy Bender Net Worth

Jeremy Bender biography

Dr. Jeremy Bender has been appointed as Director of the Company effective 10/1/2020. Dr. Bender is a senior biopharma leader with broad experience driving strategic decisions and transactions. Dr. Bender was recently appointed Chief Executive Officer of DayOne Biopharmaceuticals, Inc. He previously served as Vice President of Corporate Development at Gilead Sciences, Inc. where he was responsible for development and negotiation of partnerships, alliances, joint ventures, equity investments, licensing agreements, and M&A transactions including Gilead's $4.9 billion acquisition of Forty Seven, Inc., and the establishment of a 10-year partnership with Arcus Biosciences Inc. to advance next-generation cancer immunotherapies. Dr. Bender joined Gilead from Tizona Therapeutics, Inc. where he was Chief Operating Officer responsible for the Company's finance, operations, alliance, and corporate development activities. Prior to Tizona, Dr. Bender was Chief Business Officer of Sutro Biopharma, Inc. where he was responsible for business development, alliance and project management, external communications, and intellectual property strategy. During his time at Sutro, he completed partnering transactions with Celgene Corporation and EMD Serono. Dr. Bender received his undergraduate degree in Biological Sciences from Stanford University and his Ph.D.in Microbiology & Immunology from the University of Colorado, where he worked on peripheral T-cell selection in the labs of Philippa Marrack and John Kappler. He also received an M.B.A. from the MIT Sloan School of Management.

How old is Jeremy Bender?

Jeremy Bender is 49, he's been the Director of Mereo BioPharma plc since 2020. There are 20 older and 1 younger executives at Mereo BioPharma plc. The oldest executive at Mereo BioPharma Group plc is Peter Fellner, 76, who is the Non-Executive Independent Chairman of the Board.

What's Jeremy Bender's mailing address?

Jeremy's mailing address filed with the SEC is C/O MEREO BIOPHARMA GROUP PLC, 4TH FLOOR, ONE CAVENDISH PLACE, LONDON, X0, W1G 0QF.

Insiders trading at Mereo BioPharma plc

Over the last few years, insiders at Mereo BioPharma plc have traded over $974,160 worth of Mereo BioPharma plc stock. The most active insiders traders include Capital Management Lp Rosen..., Deepika Pakianathan, and Denise Scots Knight. On average, Mereo BioPharma plc executives and independent directors trade stock every 8 days with the average trade being worth of $447,435. The most recent stock trade was executed by Deepika Pakianathan on 22 August 2024, trading 105,244 units of MREO stock currently worth $151,551.

What does Mereo BioPharma plc do?

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Mereo BioPharma plc executives and stock owners

Mereo BioPharma plc executives and other stock owners filed with the SEC include:

• Denise Scots-Knight,
  Chief Executive Officer, Co-Founder, Executive Director
• Dr. Denise Scots-Knight Ph.D.,
  Co-Founder, CEO & Exec. Director
• Charles Sermon,
  Co-Founder, Gen. Counsel & Company Sec.
• Dr. Alastair MacKinnon M.D., MBBS,
  Co-Founder and Chief of Portfolio & Pipeline Strategy
• Dr. John P. Richard M.B.A., MBA,
  Co-Founder & Chief Bus. Officer
• Dr. John A. Lewicki Ph.D.,
  Chief Scientific Officer
• Alexandra Hughes-Wilson,
  Chief of Patient Access & Commercial Planning
• Richard Jones,
  Chief Financial Officer, Executive Director
• Peter Fellner,
  Non-Executive Independent Chairman of the Board
• Anders Ekblom,
  Non-Executive Independent Director
• Peter Bains,
  Non-Executive Independent Director
• Kunal Kashyap,
  Non-Executive Independent Director
• Michael Wyzga,
  Non-Executive Independent Director
• Deepa Pakianathan,
  Non-Executive Independent Director
• Brian Schwartz,
  Director
• Jeremy Bender,
  Director
• Wills Hughes-Wilson,
  Head of Patient Access, Commercial Planning
• Heidi Petersen,
  Senior Vice President, Regulatory Affairs
• Jill Henrich,
  U.S. Site Head and Senior Vice President of Regulatory Affairs
• John Richard,
  Head of Corporate Development, Co-Founder
• Alastair MacKinnon,
  Co-Founder, Chief Medical Officer
• Charles Sermon,
  Co-Founder, General Counsel, Company Secretary
• Dr. Arun Mistry,
  Therapeutic Area Head of Setrusumab
• Dr. Jackie Parkin,
  Therapy Area Head of Respiratory Endocrinology
• Ian Hodgson,
  Head of Clinical Operations
• Dr. Fiona Bor,
  Head of Intellectual Property
• Dr. John A. Lewicki,
  Chief Scientific Officer
• Christine Fox CPA,
  Chief Financial Officer
• Jill Henrich,
  US Site Head & Sr. VP of Regulatory Affairs
• John Richard,
  Co-Founder & Head of Corp. Devel.
• Dr. Alastair MacKinnon,
  Co-Founder & Chief Medical Officer
• Dr. Denise Scots-Knight,
  Co-Founder, CEO & Exec. Director
• Capital Management Lp Rosen...,
  
• Marc J Yoskowitz,
  
• Annalisa Jenkins,
  
• Daniel Shames,
  
• Deepika Pakianathan,
  
• Pierre Jacquet,
  
• Christine Ann Fox,
  Chief Financial Officer
• John A. Lewicki,
  Chief Scientific Officer